Skip to content
PICO Portalanswers from OpenAlex

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

PaperCitations, authors & open-access status

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China is a paper indexed in PICO Portal from OpenAlex.

How many citations does Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China have?

PICO Portalcitation count

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China has 259 citations in the OpenAlex counts PICO Portal stores.

When was Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China published?

PICO Portalyear

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China has 2017 year in the PICO Portal index.

What is the open-access status of Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China?

PICO Portaloa status

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China has gold oa status in the PICO Portal index.

What is the DOI of Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China?

PICO Portaldoi

The DOI for Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China is on the source record.

What is the PMID of Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China?

PICO Portalpmid

The PMID for Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China is on the source record.

What is the OpenAlex record for Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China?

PICO Portalopenalex

The OpenAlex for Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial